These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 22927417)

  • 21. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
    Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
    Isnaldi E; Ferraioli D; Ferrando L; Brohée S; Ferrando F; Fregatti P; Bedognetti D; Ballestrero A; Zoppoli G
    Breast Cancer Res Treat; 2019 Sep; 177(2):335-343. PubMed ID: 31222709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11.
    Yin YP; Ma LY; Cao GZ; Hua JH; Lv XT; Lin WC
    Acta Pharmacol Sin; 2022 Aug; 43(8):2119-2127. PubMed ID: 34893686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents.
    Gartrell J; Mellado-Largarde M; Clay MR; Bahrami A; Sahr NA; Sykes A; Blankenship K; Hoffmann L; Xie J; Cho HP; Twarog N; Connelly M; Yan KK; Yu J; Porter SN; Pruett-Miller SM; Neale G; Tinkle CL; Federico SM; Stewart EA; Shelat AA
    Mol Cancer Ther; 2021 Nov; 20(11):2151-2165. PubMed ID: 34413129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
    Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
    Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
    Winkler C; Armenia J; Jones GN; Tobalina L; Sale MJ; Petreus T; Baird T; Serra V; Wang AT; Lau A; Garnett MJ; Jaaks P; Coker EA; Pierce AJ; O'Connor MJ; Leo E
    Br J Cancer; 2021 Mar; 124(5):951-962. PubMed ID: 33339894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
    Zhang B; Stewart CA; Wang Q; Cardnell RJ; Rocha P; Fujimoto J; Solis Soto LM; Wang R; Novegil V; Ansell P; He L; Fernandez L; Jendrisak A; Gilbertson C; Schonhoft JD; Byun J; Jones J; Anderson AKL; Aparicio A; Tran H; Negrao MV; Zhang J; Wang WL; Wistuba II; Wang J; Wenstrup R; Byers LA; Gay CM
    Br J Cancer; 2022 Aug; 127(3):569-576. PubMed ID: 35440668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic upregulation of Schlafen11 renders 
WNT- and SHH-activated medulloblastomas sensitive to cisplatin.
    Nakata S; Murai J; Okada M; Takahashi H; Findlay TH; Malebranche K; Parthasarathy A; Miyashita S; Gabdulkhaev R; Benkimoun I; Druillennec S; Chabi S; Hawkins E; Miyahara H; Tateishi K; Yamashita S; Yamada S; Saito T; On J; Watanabe J; Tsukamoto Y; Yoshimura J; Oishi M; Nakano T; Imamura M; Imai C; Yamamoto T; Takeshima H; Sasaki AT; Rodriguez FJ; Nobusawa S; Varlet P; Pouponnot C; Osuka S; Pommier Y; Kakita A; Fujii Y; Raabe EH; Eberhart CG; Natsumeda M
    Neuro Oncol; 2023 May; 25(5):899-912. PubMed ID: 36273330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.
    Kaur S; Schwartz AL; Jordan DG; Soto-Pantoja DR; Kuo B; Elkahloun AG; Mathews Griner L; Thomas CJ; Ferrer M; Thomas A; Tang SW; Rajapakse VN; Pommier Y; Roberts DD
    Front Oncol; 2019; 9():994. PubMed ID: 31632920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines.
    Iwasaki J; Komori T; Nakagawa F; Nagase H; Uchida J; Matsuo K; Uto Y
    Anticancer Res; 2019 Jul; 39(7):3553-3563. PubMed ID: 31262879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SLFN11 inhibits checkpoint maintenance and homologous recombination repair.
    Mu Y; Lou J; Srivastava M; Zhao B; Feng XH; Liu T; Chen J; Huang J
    EMBO Rep; 2016 Jan; 17(1):94-109. PubMed ID: 26658330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells.
    Okamoto Y; Abe M; Mu A; Tempaku Y; Rogers CB; Mochizuki AL; Katsuki Y; Kanemaki MT; Takaori-Kondo A; Sobeck A; Bielinsky AK; Takata M
    Blood; 2021 Jan; 137(3):336-348. PubMed ID: 32735670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy.
    Hamada S; Kano S; Murai J; Suzuki T; Tsushima N; Mizumachi T; Suzuki M; Takashima T; Taniyama D; Sakamoto N; Fujioka Y; Ohba Y; Homma A
    Front Oncol; 2022; 12():978875. PubMed ID: 36741698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
    He T; Zhang M; Zheng R; Zheng S; Linghu E; Herman JG; Guo M
    Epigenomics; 2017 Jun; 9(6):849-862. PubMed ID: 28403629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schlafen 11 Restricts Flavivirus Replication.
    Valdez F; Salvador J; Palermo PM; Mohl JE; Hanley KA; Watts D; Llano M
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31118262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
    Kundu K; Cardnell RJ; Zhang B; Shen L; Stewart CA; Ramkumar K; Cargill KR; Wang J; Gay CM; Byers LA
    Transl Lung Cancer Res; 2021 Nov; 10(11):4095-4105. PubMed ID: 35004241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
    Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y
    Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR.
    Mao S; Chaerkady R; Yu W; D'Angelo G; Garcia A; Chen H; Barrett AM; Phipps S; Fleming R; Hess S; Koopmann JO; Dimasi N; Wilson S; Pugh K; Cook K; Masterson LA; Gao C; Wu H; Herbst R; Howard PW; Tice DA; Cobbold M; Harper J
    Mol Cancer Ther; 2021 Mar; 20(3):541-552. PubMed ID: 33653945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.